September 17, 2018 Sequana Medical announces presentation of pre-clinical proof of concept results of its Direct Sodium Removal (DSR) therapy for the management of volume overload in heart failure at the Annual Scientific Meeting of the Heart Failure Society of America (HFSA) Non-regulated EN
July 12, 2018 Sequana Medical Announces the Appointment of Kirsten Van Bockstaele as Chief Financial Officer Non-regulated EN
May 17, 2018 Sequana Medical announces inclusion of alfapump® in EASL Clinical Practice Guidelines and presentation of study demonstrating physical component of QOL is predictor of mortality in refractory ascites. Non-regulated
March 20, 2018 Sequana Medical Announces Publication of Results of Multicentre Randomized Controlled Study Non-regulated EN
March 19, 2018 Sequana Medical Announces Publication of Results of Multicentre Randomized Controlled Study: Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis Non-regulated
October 24, 2017 Sequana Medical Announces Results of the MOSAIC trial data presented at 2017 AASLD Non-regulated
October 4, 2017 Sequana Medical Announces Publication of Results of alfapump® Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology & Therapeutics (AP&T). Non-regulated EN
July 6, 2017 Sequana Medical announces publication of results of Multicentre Randomized Controlled Study for the alfapump® Non-regulated